Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 4, 2026, 5:47 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–12 of 12 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Panitumumab-IRDye800 Clear all
Recruiting Phase 1Phase 2 Interventional

Panitumumab-IRDye800 in Diagnosing Participants With Malignant Glioma Undergoing Surgery

NCT03510208
View directory record Official record
Conditions
Malignant Brain Neoplasm, Malignant Glioma
Interventions
Near-Infrared Fluorescence Imaging, Panitumumab, Panitumumab-IRDye800, POINPOINT-IR9000
Procedure · Biological · Drug + 1 more
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Jun 29, 2026 · Synced Nov 4, 2026, 5:47 PM EST
Recruiting Phase 1 Interventional

Evaluating the Use of Dual Imaging Techniques for Detection of Disease in Patients With Head and Neck Cancer

NCT05945875
View directory record Official record
Conditions
Head and Neck Squamous Cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma
Interventions
Panitumumab-IRDye800, Indium In 111 Panitumumab, Single Photon Emission Computed Tomography, Computed Tomography, Resection, Fluorescence Imaging
Drug · Other · Procedure
Lead sponsor
Vanderbilt-Ingram Cancer Center
Other
Eligibility
19 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Oct 3, 2025 · Synced Nov 4, 2026, 5:47 PM EST
Recruiting Early Phase 1 Interventional

Pilot Study Evaluating Panitumumab-IRDye800 as an Optical Imaging Agent to Detect Intracranial Lesions During Neurosurgical Procedures

NCT07493447
View directory record Official record
Conditions
Meningioma, Glioblastoma, Acoustic Neuroma, Brain Cancer, Pituitary Adenoma
Interventions
Panitumumab-IRDye800
Drug
Lead sponsor
Eben Rosenthal
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Nov 4, 2026, 5:47 PM EST
Recruiting Phase 1Phase 2 Interventional

Panitumumab-IRDye800 in Detecting Cancer in Participants With Lung Cancer During Surgery

NCT03582124
View directory record Official record
Conditions
Lung Carcinoma, Metastatic Malignant Neoplasm in the Lung, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8
Interventions
Near-Infrared Fluorescence Imaging, Panitumumab-IRDye800, Pharmacokinetic Study, Therapeutic Conventional Surgery
Procedure · Drug · Other
Lead sponsor
Stanford University
Other
Eligibility
19 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Oct 5, 2026 · Synced Nov 4, 2026, 5:47 PM EST
Completed Phase 1 Interventional

Panitumumab IRDye800 Optical Imaging Study

NCT02415881
View directory record Official record
Conditions
Head and Neck Cancer
Interventions
Panitumumab IRDye 800, da Vinci Firefly, IMAGE1 + ICG Hopkins telescope and/or VITOM
Drug · Device
Lead sponsor
Eben Rosenthal
Other
Eligibility
19 Years and older
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
2
States / cities
Birmingham, Alabama • Stanford, California
Source: ClinicalTrials.gov public record
Updated Sep 24, 2021 · Synced Nov 4, 2026, 5:47 PM EST
Completed Phase 2 Interventional Results available

Panitumumab-IRDye800 Compared to Sentinel Node Biopsy and (Selective) Neck Dissection in Identifying Metastatic Lymph Nodes in Patients With Head&Neck Cancer

NCT03405142
View directory record Official record
Conditions
Head and Neck Squamous Cell Carcinoma, Squamous Cell Carcinoma of the Head and Neck (SCCHN), Head and Neck Cancer
Interventions
Panitumumab-IRDye800, Lymphoseek
Drug
Lead sponsor
Eben Rosenthal
Other
Eligibility
19 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Nov 10, 2022 · Synced Nov 4, 2026, 5:47 PM EST
Recruiting Phase 1 Interventional

Window Trial of Fluorescently Labeled Panitumumab (Panitumumab-IRDye800) in Head and Neck Cancer

NCT06819228
View directory record Official record
Conditions
HNSCC, HNSCC,Larynx, Pharynx and Oral Cavity, SCC - Squamous Cell Carcinoma
Interventions
Panitumumab IRDye 800
Drug
Lead sponsor
Vanderbilt-Ingram Cancer Center
Other
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Aug 3, 2026 · Synced Nov 4, 2026, 5:47 PM EST
Recruiting Phase 1 Interventional

Study Evaluating the Safety and Feasibility of Panitumumab-IRDye800 and [18F]NOTA-ABY-030 for Targeted Dual-Modality Imaging (TDMI) in Head and Neck Squamous Cell Carcinoma

NCT07741643
View directory record Official record
Conditions
HNSCC,Larynx, Pharynx and Oral Cavity, Squamous Cell Carcinoma, Head and Neck Cancer, Head and Neck Surgery
Interventions
Panitumumab-IRDye800, [18F]NOTA-ABY-030
Drug
Lead sponsor
Vanderbilt-Ingram Cancer Center
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Oct 19, 2026 · Synced Nov 4, 2026, 5:47 PM EST
Recruiting Phase 1Phase 2 Interventional

Panitumumab-IRDye800 to Detect Pediatric Neoplasms During Neurosurgical Procedures

NCT04085887
View directory record Official record
Conditions
Brain Tumor
Interventions
Panitumumab-IRDye800, Pinpoint-IR9000 endoscopic/handheld device, Explorer Air camera, PDE-NEO-II
Drug · Device
Lead sponsor
Stanford University
Other
Eligibility
6 Months to 25 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Sep 29, 2026 · Synced Nov 4, 2026, 5:47 PM EST
Recruiting Phase 1Phase 2 Interventional

Panitumumab-IRDye800 in Patients With Pancreatic Cancer Undergoing Surgery

NCT03384238
View directory record Official record
Conditions
Pancreatic Adenocarcinoma
Interventions
Fluorescence Imaging, Panitumumab, Panitumumab-IRDye800
Procedure · Biological · Drug
Lead sponsor
George Poultsides
Other
Eligibility
19 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Mar 17, 2026 · Synced Nov 4, 2026, 5:47 PM EST
Recruiting Phase 2 Interventional

Phase II Panitumumab-IRDye800 in Head & Neck Cancer

NCT04511078
View directory record Official record
Conditions
Head and Neck Cancer
Interventions
Panitumumab-IRDye800
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2030
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Dec 24, 2025 · Synced Nov 4, 2026, 5:47 PM EST
Completed Phase 1 Interventional Results available

Panitumumab-IRDye800 and 89Zr-Panitumumab in Identifying Metastatic Lymph Nodes in Patients With Squamous Cell Head and Neck Cancer

NCT03733210
View directory record Official record
Conditions
Squamous Cell Carcinoma of the Head and Neck, Carcinoma of the Head and Neck
Interventions
Panitumumab-IRDye800, 89-Zirconium (Zr-89) Panitumumab, Pinpoint IR IR9000 fluorescence imaging system (FIS), SPY-PHI IR9000 fluorescence imaging system (FIS), Explorer Air camera, PDE-NEO II camera, FIS-00 fluorescence imaging system (FIS), Da Vinci Firefly Imaging System, IGP-ELVIS-v4 Macroscopic Specimen Imager, Vevo 3100 LAZR-X, Pearl Triology Imaging System, Odyssey CLx Imaging System, Leica fluorescence microscope
Drug · Device
Lead sponsor
Andrei Iagaru
Other
Eligibility
19 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated May 19, 2023 · Synced Nov 4, 2026, 5:47 PM EST